Cox proportional hazard regression analysis for immunohistochemically defined non-GC and GC groups
| Survival . | Non-GC . | GC . | ||||
|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| FFS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 1.704 | 1.001-2.903 | .050 | 3.274 | 1.645-6.518 | .001 |
| Treatment | ||||||
| Control or rituximab | 0.341 | 0.186-0.627 | .001 | 0.596 | 0.298-1.191 | .143 |
| OS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.610 | 1.412-4.824 | .002 | 4.383 | 1.964-9.779 | < .001 |
| Treatment | ||||||
| Control or rituximab | 0.296 | 0.139-0.631 | .002 | 0.600 | 0.268-1.343 | .214 |
| Survival . | Non-GC . | GC . | ||||
|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |
| FFS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 1.704 | 1.001-2.903 | .050 | 3.274 | 1.645-6.518 | .001 |
| Treatment | ||||||
| Control or rituximab | 0.341 | 0.186-0.627 | .001 | 0.596 | 0.298-1.191 | .143 |
| OS | ||||||
| IPI | ||||||
| 0 to 2 or 3 to 5 | 2.610 | 1.412-4.824 | .002 | 4.383 | 1.964-9.779 | < .001 |
| Treatment | ||||||
| Control or rituximab | 0.296 | 0.139-0.631 | .002 | 0.600 | 0.268-1.343 | .214 |
RR indicates relative risk; CI, confidence interval; IPI, higher IPI worse; and treatment, control worse than rituximab.